Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company's lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024.
Indaptus Therapeutics, Inc（纳斯达克代码: INDP) 是一家临床阶段生物技术公司，致力于开创创新癌症和病毒感染治疗，今天宣布该公司的首席医学官Roger Waltzman医学博士将于2024年6月20日至21日在波士顿举行的第七届下一代免疫肿瘤学大会上，就其先导产品候选Decoy20进行更新报告。
Dr. Waltzman will present preliminary results from the Company's ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.
Waltzman博士将介绍公司正在进行的Decoy20第一期研究的初步结果，这是一种使用杀死细菌的静脉治疗，旨在广泛刺激免疫系统，用于对抗晚期实体瘤患者。